AGEs‐RAGE System Mediates Atrial Structural Remodeling in the Diabetic Rat

Background: Diabetes mellitus (DM) is one of the independent risk factors for atrial fibrillation (AF). Our previous study has indicated that DM causes atrial structural remodeling with intraatrial conduction disturbances. We tested the hypothesis that the advanced glycation end products (AGEs) and the receptor for AGE (RAGE), which have been implicated in diabetic complications, are responsible for the atrial structural remodeling.

[1]  J. Finsterer,et al.  Diabetic atrial fibrillation patients: mortality and risk for stroke or embolism during a 10‐year follow‐up , 2003, Diabetes/metabolism research and reviews.

[2]  X. Chen,et al.  RAGE and amyloid-β peptide neurotoxicity in Alzheimer's disease , 1996, Nature.

[3]  F A Mathewson,et al.  The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. , 1995, The American journal of medicine.

[4]  D. Reda,et al.  Amiodarone versus sotalol for atrial fibrillation. , 2005, The New England journal of medicine.

[5]  V. Hwa,et al.  Connective tissue growth factor/IGF-binding protein-related protein-2 is a mediator in the induction of fibronectin by advanced glycosylation end-products in human dermal fibroblasts. , 2002, Endocrinology.

[6]  M. Movahed,et al.  Diabetes mellitus is a strong, independent risk for atrial fibrillation and flutter in addition to other cardiovascular disease. , 2005, International journal of cardiology.

[7]  K. O. Elliston,et al.  Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. , 1992, The Journal of biological chemistry.

[8]  H. Sokabe,et al.  Does so-called streptozocin hypertension exist in rats? , 1987, Hypertension.

[9]  J. Yee,et al.  Regulation of connective tissue growth factor activity in cultured rat mesangial cells and its expression in experimental diabetic glomerulosclerosis. , 2000, Journal of the American Society of Nephrology : JASN.

[10]  M. Katovich,et al.  Effects of Streptozotocin-Induced Diabetes and Insulin Treatment on Blood Pressure in the Male Rat , 1995, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[11]  L. Thal,et al.  Blood Levels of Alpha-1-Antichymotrypsin and Risk Factors for Alzheimer’s Disease: Effects of Gender and Apolipoprotein E Genotype , 2000, Dementia and Geriatric Cognitive Disorders.

[12]  B. Gersh,et al.  Atrial fibrillation: a perspective: thinking inside and outside the box. , 2004, Circulation.

[13]  A. Schmidt,et al.  Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts , 1998, Nature Medicine.

[14]  D. Severson,et al.  Type I and II models of diabetes produce different modifications of K+ currents in rat heart: role of insulin , 1998, The Journal of physiology.

[15]  P. Grant,et al.  Effects of novel polymorphisms in the RAGE gene on transcriptional regulation and their association with diabetic retinopathy. , 2001, Diabetes.

[16]  W. Hurley,et al.  Isolation and characterization of two binding proteins for advanced glycosylation end products from bovine lung which are present on the endothelial cell surface. , 1992, The Journal of biological chemistry.

[17]  Z. Makita,et al.  Advanced Glycation End Product-induced Apoptosis and Overexpression of Vascular Endothelial Growth Factor and Monocyte Chemoattractant Protein-1 in Human-cultured Mesangial Cells* , 2002, The Journal of Biological Chemistry.

[18]  T. Kislinger,et al.  Blockade of RAGE–amphoterin signalling suppresses tumour growth and metastases , 2000, Nature.

[19]  K. Preissner,et al.  The Pattern Recognition Receptor (RAGE) Is a Counterreceptor for Leukocyte Integrins , 2003, The Journal of experimental medicine.

[20]  E. Stier,et al.  Receptors for advanced glycation end-products (AGE)—expression by endothelial cells in non-diabetic uraemic patients , 1996 .

[21]  T. Igarashi,et al.  Chronic hypertension induced by streptozotocin in rats , 1978, Naunyn-Schmiedeberg's Archives of Pharmacology.

[22]  G. O. Carrier,et al.  Influence of Short‐Term Experimental Diabetes on Blood Pressure and Heart Rate in Response to Norepinephrine and Angiotensin II in the Conscious Rat , 1983, Journal of cardiovascular pharmacology.

[23]  M. Takigawa,et al.  Inhibition of endogenous expression of connective tissue growth factor by its antisense oligonucleotide and antisense RNA suppresses proliferation and migration of vascular endothelial cells. , 1998, Journal of biochemistry.

[24]  D. Levy,et al.  Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. , 1998, Circulation.

[25]  R. Wada,et al.  Effects of OPB‐9195, anti‐glycation agent, on experimental diabetic neuropathy , 2001, European journal of clinical investigation.

[26]  Merlin C. Thomas,et al.  A Breaker of Advanced Glycation End Products Attenuates Diabetes‐Induced Myocardial Structural Changes , 2003, Circulation research.

[27]  S. Takasawa,et al.  Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice. , 2001, The Journal of clinical investigation.

[28]  D. Singer,et al.  Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. , 2001, JAMA.

[29]  Z. Makita,et al.  Suppression of transforming growth factor beta and vascular endothelial growth factor in diabetic nephropathy in rats by a novel advanced glycation end product inhibitor, OPB-9195 , 1999, Diabetologia.

[30]  S. Lévy,et al.  Characterization of different subsets of atrial fibrillation in general practice in France: the ALFA study. The College of French Cardiologists. , 1999, Circulation.

[31]  L. Råstam,et al.  Atrial fibrillation and its association with type 2 diabetes and hypertension in a Swedish community , 2004, Diabetes, obesity & metabolism.

[32]  S. Kaneko,et al.  What are Arrhythmogenic Substrates in Diabetic Rat Atria? , 2006, Journal of cardiovascular electrophysiology.

[33]  J. Chen,et al.  The Receptor for Advanced Glycation End Products (RAGE) Is a Cellular Binding Site for Amphoterin , 1995, The Journal of Biological Chemistry.

[34]  P A Wolf,et al.  Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. , 1998, The American journal of cardiology.

[35]  F. Martin,et al.  Suppression Subtractive Hybridization Identifies High Glucose Levels as a Stimulus for Expression of Connective Tissue Growth Factor and Other Genes in Human Mesangial Cells* , 1999, The Journal of Biological Chemistry.

[36]  C. Soto,et al.  Receptor-dependent cell stress and amyloid accumulation in systemic amyloidosis , 2000, Nature Network Boston.

[37]  M. Domanski,et al.  Relationships Between Sinus Rhythm, Treatment, and Survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study , 2004, Circulation.

[38]  G. Lip,et al.  Diabetes mellitus and atrial fibrillation: perspectives on epidemiological and pathophysiological links. , 2005, International journal of cardiology.

[39]  J. Yamamoto.  Blood pressure and metabolic effects of streptozotocin in Wistar-Kyoto and spontaneously hypertensive rats. , 1988, Clinical and experimental hypertension. Part A, Theory and practice.

[40]  M. Cooper,et al.  Prevention of Accelerated Atherosclerosis by Angiotensin-Converting Enzyme Inhibition in Diabetic Apolipoprotein E–Deficient Mice , 2002, Circulation.

[41]  P. Wolf,et al.  Characteristics and prognosis of lone atrial fibrillation. 30-year follow-up in the Framingham Study. , 1985, JAMA.

[42]  J. Seward,et al.  The changing epidemiology and natural history of nonvalvular atrial fibrillation: clinical implications. , 2004, Transactions of the American Clinical and Climatological Association.

[43]  M. Cooper,et al.  Renal connective tissue growth factor induction in experimental diabetes is prevented by aminoguanidine. , 2002, Endocrinology.

[44]  Gary R. Grotendorst.  Connective tissue growth factor: a mediator of TGF-β action on fibroblasts , 1997 .

[45]  P. Korantzopoulos,et al.  The Association of Metabolic Syndrome with Atrial Fibrillation: An Emerging Epidemiological and Pathophysiological Hypothesis , 2005, Cardiology.

[46]  A. Schmidt,et al.  RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. , 1996, Nature.

[47]  A. Schmidt,et al.  Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. , 1999, Circulation research.

[48]  V. D’Agati,et al.  RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. , 2003, The American journal of pathology.

[49]  L. Lau,et al.  Fisp12/Mouse Connective Tissue Growth Factor Mediates Endothelial Cell Adhesion and Migration through Integrin αvβ3, Promotes Endothelial Cell Survival, and Induces Angiogenesis In Vivo , 1999, Molecular and Cellular Biology.

[50]  J. Magyar,et al.  Action potentials and potassium currents in rat ventricular muscle during experimental diabetes. , 1992, Journal of molecular and cellular cardiology.

[51]  V. D’Agati,et al.  Receptor for Advanced Glycation End Products Mediates Inflammation and Enhanced Expression of Tissue Factor in Vasculature of Diabetic Apolipoprotein E–Null Mice , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[52]  Gary R. Grotendorst,et al.  Stimulation of fibroblast cell growth, matrix production, and granulation tissue formation by connective tissue growth factor. , 1996, The Journal of investigative dermatology.

[53]  E. Stier,et al.  Receptors for advance glycation end-products (AGE) - expression by endothelial cells in non-diabetic uraemic patients. , 1996, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[54]  P. Schattner,et al.  An Update on the Etiology and Epidemiology of Diabetes Mellitus , 2006, Annals of the New York Academy of Sciences.

[55]  T. Tomita,et al.  Streptozotocin Diabetic Rats Are Hypertensive Despite Reduced Hypothalamic Responsiveness , 1982, Hypertension.

[56]  Z. Makita,et al.  Progression of Nephropathy in Spontaneous Diabetic Rats Is Prevented by OPB-9195, a Novel Inhibitor of Advanced Glycation , 1997, Diabetes.

[57]  M. Neurath,et al.  RAGE Mediates a Novel Proinflammatory Axis A Central Cell Surface Receptor for S100/Calgranulin Polypeptides , 1999, Cell.